Patents by Inventor Joel Kralj

Joel Kralj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200191776
    Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but—for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context.
    Type: Application
    Filed: February 24, 2020
    Publication date: June 18, 2020
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
  • Patent number: 10613079
    Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: April 7, 2020
    Assignee: Q-STATE BIOSCIENCES, INC.
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
  • Patent number: 10352945
    Abstract: The invention provides methods, cells and constructs for optical measurement of membrane potential. These methods can be used in cells that are not accessible to presently available methods using electrodes. The methods can be directed to, for example, high-throughput drug screening assays to determine agents that can affect membrane potential of a target cell.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: July 16, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Adam Ezra Cohen, Joel Kralj, Adam D. Douglass
  • Publication number: 20190025291
    Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 24, 2019
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
  • Patent number: 10161937
    Abstract: The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: December 25, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: Adam Ezra Cohen, Joel Kralj, Adam D. Douglass, Daniel Hochbaum
  • Patent number: 10107796
    Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: October 23, 2018
    Assignee: Q-STATE BIOSCIENCES, INC.
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
  • Patent number: 10048275
    Abstract: Screening compounds by exposing a plurality of cardiomyocytes to a compound, wherein the cardiomyocytes express an optogenetic reporter of membrane potential and an optogenetic reporter of calcium level; receiving light from the optogenetic reporter of membrane potential; creating an AP waveform using the received light; and analyzing the AP waveform to determine the presence or absence of a risk for arrhythmia associated with the compound.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: August 14, 2018
    Assignee: Q-STATE BIOSCIENCES, INC.
    Inventors: Joel Kralj, Graham Dempsey, Christopher Werley, Adam Cohen
  • Publication number: 20180031553
    Abstract: The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology.
    Type: Application
    Filed: July 10, 2017
    Publication date: February 1, 2018
    Applicant: President and Fellows of Harvard College
    Inventors: Adam Ezra Cohen, Joel Kralj, Adam D. Douglass, Daniel Hochbaum
  • Publication number: 20180031572
    Abstract: The invention provides methods, cells and constructs for optical measurement of membrane potential. These methods can be used in cells that are not accessible to presently available methods using electrodes. The methods can be directed to, for example, high-throughput drug screening assays to determine agents that can affect membrane potential of a target cell.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 1, 2018
    Applicant: President and Fellows of Harvard College
    Inventors: Adam Ezra Cohen, Joel Kralj, Adam D. Douglass
  • Patent number: 9791455
    Abstract: The invention provides methods, cells and constructs for optical measurement of membrane potential. These methods can be used in cells that are not accessible to presently available methods using electrodes. The methods can be directed to, for example, high-throughput drug screening assays to determine agents that can affect membrane potential of a target cell.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: October 17, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Adam E. Cohen, Joel Kralj, Adam D. Douglass
  • Publication number: 20170292961
    Abstract: The invention relates to methods of assessing communication between cells. Methods of the invention use optical reporters of cellular electrical activity to evaluate signal propagation between cells and can be used to study an individual synapse or a complex network of interconnected cells. Aspects of the invention provide a method for characterizing signal propagation between cells. The method includes providing a first cell containing a light-generating reporter and a second cell, in which the first cell and the second cell are in communication. The second cell may contain an optical actuator of cellular electrical activity. The second cell is exposed to a stimulus and an optical signal from the first cell is detected.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 12, 2017
    Inventors: Adam Cohen, Kevin C. Eggan, Joel Kralj, Daniel Hochbaum, Graham Dempsey
  • Patent number: 9702874
    Abstract: The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: July 11, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Adam E. Cohen, Joel Kralj, Adam D. Douglass, Daniel Hochbaum
  • Publication number: 20170115279
    Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context.
    Type: Application
    Filed: January 4, 2017
    Publication date: April 27, 2017
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
  • Patent number: 9594075
    Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: March 14, 2017
    Assignee: Q-State Biosciences, Inc.
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
  • Publication number: 20160282327
    Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 29, 2016
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
  • Publication number: 20160266144
    Abstract: Screening compounds by exposing a plurality of cardiomyocytes to a compound, wherein the cardiomyocytes express an optogenetic reporter of membrane potential and an optogenetic reporter of calcium level; receiving light from the optogenetic reporter of membrane potential; creating an AP waveform using the received light; and analyzing the AP waveform to determine the presence or absence of a risk for arrhythmia associated with the compound.
    Type: Application
    Filed: March 11, 2016
    Publication date: September 15, 2016
    Inventors: Joel Kralj, Graham Dempsey, Christopher Werley, Adam Cohen
  • Publication number: 20160069876
    Abstract: The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 10, 2016
    Applicant: President and Fellows of Harvard College
    Inventors: Adam E. Cohen, Joel Kralj, Adam D. Douglass, Daniel Hochbaum
  • Patent number: 9207237
    Abstract: The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: December 8, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Adam E. Cohen, Joel Kralj, Adam D. Douglass, Daniel Hochbaum
  • Publication number: 20150301030
    Abstract: Disease models for Parkinson's disease are disclosed comprising a dopaminergic neuron having one or more phenotypic or genotypic characteristics of Parkinson's disease where the neuron expresses an optical reporter of, and an optical activator of, electrical activity and that exhibits an optical signature in response to neural stimulation. Cells may optionally include an indicator of intracellular calcium levels. Transformed neurons may be optically evaluated for action potentials to track the development of disease, evaluate potential therapies, diagnosis of disease, and to identify mutations and genes associated with disease development and progression.
    Type: Application
    Filed: April 21, 2015
    Publication date: October 22, 2015
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
  • Publication number: 20150301029
    Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context.
    Type: Application
    Filed: April 21, 2015
    Publication date: October 22, 2015
    Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis